Skip to content
Screener

Bruker BRKR Investing Cash Flow

Investing Cash Flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$164M+157%
Danaher logo
DanaherDHR
-$10.15B-3,833%
TEC
Bio-TechneTECH
-$5.82M+34.4%
WAT
Waters CorporationWAT
$2M+103%
Agilent Technologies logo
Agilent TechnologiesA
-$77M+32.5%
908 Devices logo
908 DevicesMASS
-$1.99M-104%

Other financials

Income statement

See full
Revenue$838.5M+5.2%
Gross profit$416.0M+16.2%
Operating income-$65.3M-649%
Net income-$52.0M-784%
EPS (diluted)-$0.41-920%

Balance sheet

See full
Cash & equivalents$189.1M+96.6%
Total debt$1.8B-25.1%
Total equity$2.4B+31.9%
Total assets$6.1B-4.5%

Cash flow

See full
Operating cash flow-$77.4M+39.3%
CapEx$28.8M+35.2%
Free cash flow-$106.2M+28.6%

Valuation

See full
Market cap$7.99B+71.7%
Enterprise value$9.62B+37.7%
P/S2.3×+0.9×

Profitability

See full
Gross margin46.4%-1.8pp
Operating margin-0.9%-6.2pp
Net margin-0.6%-10.0pp
FCF margin2.7%+1.3pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.8×-0.6×
Current ratio1.8×+0.2×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Bruker’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:24 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335226
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Purchases of property, plant and equipment and intangible assets(53.0)(47.3)
Cash paid for acquisitions, net of cash acquired(16.0)(69.5)
Other investing activities, net4.0(0.4)
Net cash used in investing activities(65.0)(117.2)
Cash flows from financing activities:
Repayments of revolving line of credit(25.0)(219.1)
Proceeds from revolving line of credit195.0308.2
Repayment of long-term debt(183.6)(22.3)

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Bruker's investing cash flow?
Bruker (BRKR) reported investing cash flow of -$25.3M in Q2 2026.
How has Bruker's investing cash flow changed year-over-year?
Bruker's investing cash flow increased by 72.2% year-over-year, from -$91.1M to -$25.3M.
What is the long-term trend for Bruker's investing cash flow?
Over 3 years (2021 to 2025), Bruker's investing cash flow has grown at a 0.7% compound annual growth rate (CAGR), from -$192.4M to -$196.5M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Bruker's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude